Innate Pharma Reports First Half 2021 Financial Results and Business Update
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Polivy® with R-CHP significantly improves lymphoma outcomes
europeanpharmaceuticalreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from europeanpharmaceuticalreview.com Daily Mail and Mail on Sunday newspapers.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Innate Pharma First Quarter 2021 Report
INNATE PHARMAMay 11, 2021 GMT
Lacutamab TELLOMAK trial progresses as KIR3DL2-expressing mycosis fungoides cohort advances to Stage 2 after positive early signal
Company’s first NK cell engager selected by Sanofi as drug candidate for development
Cash position of €181.7 million¹
as of March 31, 2021
MARSEILLE, France, May 11, 2021 (GLOBE NEWSWIRE) Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its revenue and cash position for the three-month period ending March 31, 2021.
“This quarter, we have continued to execute against our strategy, successfully progressing the lacutamab TELLOMAK trial in the mycosis fungoides cohort while also advancing our first NK cell engager with our partner, Sanofi,” said Mondher Mahjoubi, Chief Executive Officer of Innate Pha